Lightcast Raises $27M Funding To Advance Single-Cell Analysis Technology

The round was led by ARCH Venture Partners, with participation from M Ventures, Illumina Ventures, +ND Capital, Longwall Ventures, and OMX Ventures.

Founded in 2019 and led by CEO Paul Loeffen, Lightcast is developing the Envisia benchtop platform, set for commercial release in 2026. The funding will support product development, manufacturing, software and strategic collaborations.

Read Also - UK Prop-tech Openmoove Receives £700K In Equity Investment

Its technology uses light to control tiny droplets, enabling functional analysis of individual cells and accelerating discoveries in biology, drug development, and advanced therapies.

“Single-cell analysis technologies have transformed how we characterize cells, but they have not fully captured how they behave,” said Paul Loeffen, PhD, CEO of Lightcast.

“Our Envisia platform was built to deliver deep functional cellular insights. This financing is a strong validation of both our technology and the momentum we are seeing with customers, and it will enable us to deliver a commercial platform that can meaningfully accelerate how new therapies are discovered and developed.”

About Lightcast

Lightcast aims to expand capabilities in single-cell analysis by building a more accessible, scalable, and flexible platform for researchers. Its technology is designed to enable new biological discoveries and accelerate the development of innovative drugs, therapies, and biologics.